MwanzoA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Bei iliyotangulia
R$ 83.44
Bei za mwaka
R$ 67.16 - R$ 132.40
Thamani ya kampuni katika soko
41.75B USD
Wastani wa hisa zilizouzwa
20.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.10B | 84.95% |
Matumizi ya uendeshaji wa biashara | 697.59M | 17.14% |
Mapato halisi | 186.42M | 322.56% |
Kiwango cha faida halisi | 16.99 | 220.33% |
Mapato kwa kila hisa | 1.25 | 1,983.33% |
EBITDA | 145.22M | 259.60% |
Asilimia ya kodi ya mapato | -15.69% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.91B | 7.94% |
Jumla ya mali | 4.97B | 17.13% |
Jumla ya dhima | 4.18B | 0.10% |
Jumla ya hisa | 789.18M | — |
hisa zilizosalia | 132.62M | — |
Uwiano wa bei na thamani | 14.00 | — |
Faida inayotokana na mali | 6.71% | — |
Faida inayotokana mtaji | 9.73% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 186.42M | 322.56% |
Pesa kutokana na shughuli | 163.56M | 272.78% |
Pesa kutokana na uwekezaji | -37.17M | 29.76% |
Pesa kutokana na ufadhili | 45.32M | 46.20% |
Mabadiliko halisi ya pesa taslimu | 166.00M | 224.03% |
Mtiririko huru wa pesa | -44.92M | 40.57% |
Kuhusu
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
14 Jun 2002
Tovuti
Wafanyakazi
2,500
